For primary resistance, it is said that approximately 30% EGFR-mutated NSCLC patients develop resistance at the beginning of EGFR-TKI treatment due to K-Ras mutation and PTEN deletion [24–27]. The gene discussed is PTEN; the disease is non-small cell lung carcinoma.